Hepatocellular carcinoma (HCC) represents the most prevalent malignancy in Egypt and globally. However, non-invasive diagnostic/prognostic biomarkers for early detection of HCC are still lacking.

Findings from the CheckMate 9DW trial support the FDA approval of nivolumab and ipilimumab in unresectable hepatocellular ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

Researchers sought to test the performance of a deep learning model system using longitudinal magnetic resonance imaging (MRI) in predicting early recurrence in patients with hepatocellular carcinoma.

David M. Dudzinski: A 59-year-old man with a history of obesity, dyslipidemia, and hypertension was evaluated in the oncology clinic of this hospital because of hepatocellular carcinoma.